# An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

> **NCT07424144** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Sanofi** · enrollment: 380 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** Itepekimab (SAR440340)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07424144
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-12
- **Primary completion:** 2028-12-12
- **Final completion:** 2028-12-12
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07424144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07424144, "An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT07424144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*